C4 Therapeutics(CCCC) - 2023 Q4 - Annual Results

• In January 2024, the previously announced $25 million stock purchase by a subsidiary of partner Betta Pharmaceuticals was completed. • In November 2023, C4T appointed Owen Hughes to its board of directors. Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance. CFT7455: • Complete Phase 1 dose exploration in R/R MM and R/R NHL by year-end 2024. • March 4, 2024: Management will present at TD Cowen's 44th Annual Health ...